959617-73-3

Basic information

• Product Name: tert-butyl 1,5-naphthyridin-3-ylcarbaMate
• Synonyms: tert-butyl 1,5-naphthyridin-3-ylcarbaMate
• CAS NO: 959617-73-3
• Molecular Formula: C13H15N3O2
• Molecular Weight: 245.2771
• Mol File: 959617-73-3.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: tert-butyl 1,5-naphthyridin-3-ylcarbaMate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 1,5-naphthyridin-3-ylcarbaMate(959617-73-3)
• EPA Substance Registry System: tert-butyl 1,5-naphthyridin-3-ylcarbaMate(959617-73-3)

Safety Data

• Hazardous Substances Data: 959617-73-3(Hazardous Substances Data)

Usage

General Description

Tert-butyl 1,5-naphthyridin-3-ylcarbamate is a chemical compound with the molecular formula C15H18N2O2. It is a carbamate derivative of 1,5-naphthyridine, a heterocyclic compound that contains both nitrogen and carbon atoms in its ring structure. The tert-butyl group on the carbamate moiety provides steric hindrance and stability to the molecule. tert-butyl 1,5-naphthyridin-3-ylcarbaMate may have potential applications in pharmaceuticals or materials science due to its unique structure and properties. However, further research is needed to fully understand its potential uses and effects.

Upstream product

• 4248-19-5 tert-butyl carbazate 
• 17965-71-8 3-bromo-1,5-naphthyridine 
• 254-79-5 1,5-naphthyridine 

Downstream Products

• 14756-77-5 3-Amino-1,5-naphthyridin 
• 959617-74-4 3-fluoro-1,5-naphthyridine 

Relevant articles and documents

CHROMENOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS

The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula (I); where A1, A2, G, R1, R2, R3, R4, and W are described herein.

COMBINATION OF KINASE INHIBITORS AND USES THEREOF

The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or a receptor tyrosine kinase (RTK) in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase α and/or an RTK in a subject. In yet another aspect, a method of inhibiting phosphorylation of Akt (S473) in a cell is set forth.

HETEROCYCLIC COMPOUNDS AND USES THEREOF

Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.